Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: OrbiMed Advisors and Viewray Inc. (VRAY)

Viewray Inc. (NASDAQ:VRAY): Samuel Isaly’s OrbiMed Advisors filed an amended 13D.

You can check out OrbiMed Advisors’ latest holdings and filings here.

Please follow OrbiMed Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings.

Samuel Isaly
Samuel Isaly
OrbiMed Advisors

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Advisors 0 9,866,102 0 9,866,102 9,866,102 13.13%
OrbiMed Capital GP III 0 9,773,034 0 9,773,034 9,773,034 13.01%
Samuel Isaly
Samuel Isaly
OrbiMed Advisors

Page 1 of 10 – SEC Filing


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
                              
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)*
    

VIEWRAY, INC.


(Name of Issuer)

COMMON STOCK


(Title of Class of Securities)

92672L107


(CUSIP Number)

OrbiMed Advisors LLC
OrbiMed Capital GP III LLC


                               
601 Lexington Avenue, 54th Floor
New York, NY 10022
Telephone:  (212) 739-6400


(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

March 2, 2018


(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Viewray Inc.
Trade (VRAY) Now!

Page 2 of 10 – SEC Filing

CUSIP No. 92672L107
1
NAME OF REPORTING PERSON

OrbiMed Advisors LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
3
SEC USE ONLY
4
SOURCE OF FUNDS

AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
                       
0
8
SHARED VOTING POWER
                   
9,866,102(1)
9
SOLE DISPOSITIVE POWER
                         
0
10
SHARED DISPOSITIVE POWER
                         
9,866,102(1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                                  
9,866,102(1)
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13.13% (2)
14
TYPE OF REPORTING PERSON (See Instructions)

IA
(1)
Includes (i) 9,458,567 outstanding shares of common stock, par value $0.01 per share (the “Shares”), of ViewRay, Inc., a Delaware corporation (the “Issuer”), and (ii) 407,535 Shares issuable upon the exercise of warrants to purchase shares (the “Warrants”).
(2)
This percentage is calculated based upon 74,744,555 Shares outstanding of the Issuer, as set forth in the Issuer’s Prospectus Supplement, filed with the Securities and Exchange Commission on February 27, 2018, and includes an additional 407,535 Shares subject to currently exercisable Warrants held by the Reporting Persons.

Follow Viewray Inc.
Trade (VRAY) Now!

Page 3 of 10 – SEC Filing

CUSIP No. 92672L107
1
NAME OF REPORTING PERSON
             
OrbiMed Capital GP III LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
3
SEC USE ONLY
4
SOURCE OF FUNDS
                     
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
                     
Delaware
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
7
SOLE VOTING POWER
                       
0
8
SHARED VOTING POWER
                    
9,773,034 (1)
9
SOLE DISPOSITIVE POWER
                    
0
10
SHARED DISPOSITIVE POWER
                   
9,773,034 (1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
                              
9,773,034 (1)
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
                  
13.01% (2)
14
TYPE OF REPORTING PERSON (See Instructions)
                     
OO
(1)
Includes (i) 9,369,342 outstanding shares of common stock, par value $0.01 per share (the “Shares”), of ViewRay, Inc., a Delaware corporation (the “Issuer”), and (ii) 403,692 Shares issuable upon the exercise of warrants to purchase shares (the “Warrants”).
(2)
This percentage is calculated based upon 74,744,555 Shares outstanding of the Issuer, as set forth in the Issuer’s Prospectus Supplement, filed with the Securities and Exchange Commission on February 27, 2018, and includes an additional 403,692 Shares subject to currently exercisable Warrants held by the Reporting Persons.

Follow Viewray Inc.
Trade (VRAY) Now!

Page 4 of 10 – SEC Filing

Item 1.
Security and Issuer
This Amendment No. 6 (“Amendment No. 6”) to Schedule 13D supplements and amends the Statement on Schedule 13D of OrbiMed Advisors LLC and OrbiMed Capital GP III LLC (the “Statement”)  originally filed with the Securities and Exchange Commission (the “SEC”) on August 26, 2016 with Samuel D. Isaly as an additional reporting person, and amended by Amendment No. 1 filed on January 20, 2017, Amendment No. 2 filed on March 17, 2017,  Amendment No. 3 filed on August 9, 2017, Amendment No. 4 filed on October 27, 2017 and Amendment No. 5 filed on January 26, 2018.  The Statement relates to the common stock, par value $0.01 per share (the “Shares”), of ViewRay, Inc., a corporation organized under the laws of Delaware (the “Issuer”), with its principal executive offices located at 2 Thermo Fisher Way, Oakwood Village, OH 44146.  The Shares are listed on the NASDAQ Global Market under the ticker symbol “VRAY.” Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
On March 2, 2018, the Issuer closed a direct registered offering announced on February 26, 2018 (the “Offering”).  The Issuer issued in the Offering a total of 7,090,581 Shares at a purchase price of $8.31 per Share and warrants (the “Warrants”) to purchase up to 1,418,116 additional Shares at a purchase price of $0.125 per Warrant with gross proceeds of $59,099,993 (the “Share Issuance”).  None of the Reporting Persons participated in the Offering.  As a result of the Share Issuance, the percentage of outstanding Shares that the Reporting Persons may be deemed to beneficially own was reduced by more than one percent of the Issuer’s Shares outstanding since the filing of Amendment No. 5 to the Statement.
Item 2.
Identity and Background
(a)          This Statement is being filed by OrbiMed Advisors LLC (“Advisors”), a limited liability company organized under the laws of Delaware, and OrbiMed Capital GP III LLC (“GP III”), a limited liability company organized under the laws of Delaware (collectively, the “Reporting Persons”).
(b) – (c), (f)          Advisors, a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole general partner of OrbiMed Associates III, LP (“Associates III”) and the sole managing member of GP III, which is the sole general partner of OrbiMed Private Investments III, LP (“OPI III”).  OPI III and Associates III hold Shares as described herein.  Advisors, and GP III have their principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
The directors and executive officers of Advisors and GP III are set forth on Schedules I and II, attached hereto.  Schedules I and II set forth the following information with respect to each such person:
(i)
name;
(ii)
business address;
(iii)
present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted;
(iv)
citizenship.
(d) – (e)          During the last five years, neither the Reporting Persons nor any Person named in Schedule I or II have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Follow Viewray Inc.
Trade (VRAY) Now!

Page 5 of 10 – SEC Filing

Item 3.
Source and Amount of Funds or Other Consideration
Not Applicable.
Item 4.
Purpose of Transaction
The Shares and Warrants initially have been acquired by the Reporting Persons for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer’s business on behalf of OPI III or Associates III.
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s Shares in particular, as well as other developments and other investment opportunities.  Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time.  If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of the Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions.  Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.
Except as set forth in this Amendment No. 6, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer’s business or corporate structure, (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.
Item 5.
Interest in Securities of the Issuer
(a) — (b)  As of the date of this filing, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares.  Based upon information contained in the Issuer’s Prospectus Supplement, dated February 25, 2018, filed with the SEC on February 27, 2018, such Shares deemed to be indirectly beneficially owned by GP III constitutes approximately 13.01% of the issued and outstanding Shares, and such Shares deemed to be indirectly beneficially owned by Advisors constitutes approximately 13.13% of the issued and outstanding Shares.  Advisors, pursuant to its authority as the sole managing member of GP III, which is the sole general partner of OPI III, and as the sole general partner of Associates III, may be deemed to indirectly beneficially own the Shares held by OPI III and Associates IIII.  GP III, pursuant to its authority as the general partner of OPI III, may be deemed to indirectly beneficially own the Shares held by OPI III.   As a result, Advisors and GP III share the power to direct the vote and the disposition of the Shares held by OPI III, and Advisors has the power to direct the vote and the disposition of the Shares held by Associates III.   Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI III and Associates III.
In addition, Advisors and GP III, pursuant to their authority under the limited partnership agreements of OPI III and/or Associates III, prior to the date of this filing, caused OPI III and Associates III, as applicable, to enter into the agreements referred to in Item 6 below.

Follow Viewray Inc.
Trade (VRAY) Now!

Page 6 of 10 – SEC Filing

(c)         The Reporting Persons have not effected any transaction during the past sixty (60) days in any Shares.
(d)         Not applicable.
(e)         Not applicable.
Item 6.
Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer
In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, GP III is the sole general partner of OPI III, pursuant to the terms of the limited partnership agreement of OPI III.  Advisors is the sole managing member of GP III, pursuant to the terms of the limited liability company agreement of GP III, and the sole general partner of Associates III, pursuant to the terms of the limited partnership agreement of Associates III.  Pursuant to these agreements and relationships, Advisors and GP III have discretionary investment management authority with respect to the assets of OPI III, and Advisors has discretionary investment management authority with respect to the assets of Associates III.  Such authority includes the power of GP III and Advisors to vote and otherwise dispose of securities purchased by OPI III, and the power of Advisors to vote and otherwise dispose of securities purchased by Associates III.  The number of outstanding Shares held of record by OPI III is 9,369,342, and the number of outstanding Shares held of record by Associates III is 89,225.  Advisors may be considered to hold indirectly 9,458,567 Shares, and GP III may be considered to hold indirectly 9,369,342 Shares.
David Bonita (“Bonita”), an employee of Advisors, has been a member of the Board of Directors of the Issuer since January 2008, and, accordingly, the Reporting Persons may have the ability to affect and influence control of the Issuer.  From time to time, Bonita may receive stock options or other awards of equity‑based compensation pursuant to the Issuer’s compensation arrangements for non‑employee directors.  Bonita is obligated to transfer any Shares issued under any such stock options or other awards, or the economic benefit thereof, to the Reporting Persons, which will in turn ensure that such Shares or economic benefits are provided to OPI III and Associates III.
Item 7.
Materials to Be Filed as Exhibits
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC, and OrbiMed Capital GP III LLC.

Follow Viewray Inc.
Trade (VRAY) Now!

Page 7 of 10 – SEC Filing

SIGNATURE
After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated:  March 6, 2018
OrbiMed Advisors LLC
By:
/s/ Jonathan T. Silverstein
Name:
 Jonathan T. Silverstein
Title:
Member of OrbiMed Advisors LLC
By:
/s/ Sven H. Borho
Name:
 Sven H. Borho
Title:
Member of OrbiMed Advisors LLC
By:
/s/ Carl L. Gordon
Name:
 Carl L. Gordon
Title:
Member of OrbiMed Advisors LLC
OrbiMed Capital GP III LLC
By:
OrbiMed Advisors LLC
its Managing Member
By:
/s/ Jonathan T. Silverstein
Name:
 Jonathan T. Silverstein
Title:
Member of OrbiMed Advisors LLC
By:
/s/ Sven H. Borho
Name:
 Sven H. Borho
Title:
Member of OrbiMed Advisors LLC
By:
/s/ Carl L. Gordon
Name:
 Carl L. Gordon
Title:
Member of OrbiMed Advisors LLC

Follow Viewray Inc.
Trade (VRAY) Now!

Page 8 of 10 – SEC Filing

Schedule I
The name and present principal occupation of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below.  Unless otherwise noted, each of these persons are United States citizens and have as their business address 601 Lexington Avenue, 54th Floor, New York, NY 10022.
Name
Position with Reporting
Person
Principal Occupation
Samuel D. Isaly
Managing Member
Managing Member
OrbiMed Advisors LLC
Carl L. Gordon
Member
Member
OrbiMed Advisors LLC
Sven H. Borho
German and Swedish Citizen
Member
Member
OrbiMed Advisors LLC
Jonathan T. Silverstein
Member
Member
OrbiMed Advisors LLC
W. Carter Neild
Member
Member
OrbiMed Advisors LLC
Geoffrey C. Hsu
Member
Member
OrbiMed Advisors LLC
Evan D. Sotiriou
Chief Financial Officer
Chief Financial Officer
OrbiMed Advisors LLC

Follow Viewray Inc.
Trade (VRAY) Now!

Page 9 of 10 – SEC Filing

Schedule II
The business and operations of OrbiMed Capital GP III LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth on Schedule I.

Follow Viewray Inc.
Trade (VRAY) Now!

Page 10 of 10 – SEC Filing

EXHIBIT INDEX
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC, and OrbiMed Capital GP III LLC.

Follow Viewray Inc.
Trade (VRAY) Now!